Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;34(9):e14022.
doi: 10.1111/pai.14022.

Next-Gen biotherapeutics: A systematic review and network meta-analysis on postbiotics as treatment for pediatric atopic dermatitis

Carol Stephanie C Tan Lim  1 , Ma Easter Joy V Sajo  2 , Khianne Ed Miguel P Orteza  2 , Patricia Barbara A Fernandez  2 , Ma Junella C Vila  2
Affiliations

Next-Gen biotherapeutics: A systematic review and network meta-analysis on postbiotics as treatment for pediatric atopic dermatitis

Carol Stephanie C Tan Lim et al. Pediatr Allergy Immunol. 2023 Sep.

Abstract

Background: Due to the recency of the postbiotic field, no head-to-head postbiotic studies have investigated its biotherapeutic potential for atopic dermatitis (AD). No network meta-analysis (NMA) has been conducted to synthesize relevant studies comparing postbiotic interventions for AD.

Objective: To assess the comparative efficacy and safety of postbiotic strains in the treatment of pediatric AD.

Methodology: This was an NMA of randomized controlled studies that evaluated postbiotics in treating pediatric AD. Systematic search of databases and registers from inception to November 30, 2022. Three authors independently performed the search, screening, and appraisal using the Cochrane risk-of-bias tool version 2 and data extraction. Data analysis was performed using STATA14 software.

Results: Nine studies evaluated eight postbiotic preparations. Lactobacillus rhamnosus IDCC 3201 (LR) ranked highest in the efficacy outcome. Compared to placebo, LR may be effective in reducing symptoms of atopic dermatitis in the main analysis (SMD -0.53, 95%CI -1.02 to -0.04) and sensitivity analysis involving studies that used SCORAD (MD -5.52, 95% CI -10.46 to -0.58), based on low-certainty evidence. Based on moderate-certainty evidence, LR probably did not increase the risk of adverse events (RR 0.97, 95% CI 0.79, 1.21). Although Lactobacillus paracasei GM080 (LP2) ranked highest in the safety outcome, it may not reduce AD symptoms compared to placebo (SMD -0.03, 95% CI -0.37, 0.32) based on low-certainty evidence.

Conclusion: LR showed significant benefits in children with AD based on low-certainty evidence. Further investigation of LR is recommended.

Keywords: atopic dermatitis; network meta-analysis; pediatrics; postbiotics; probiotics.

PubMed Disclaimer

References

REFERENCES

    1. Huang R, Ning H, Shen M, Li J, Zhang J, Chen X. Probiotics for the treatment of atopic dermatitis in children: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol. 2017;7:392. doi:10.3389/fcimb.2017.00392
    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8-16. doi:10.1159/000370220
    1. Gabriel MT, Lim HG, Gulmatico-Flores Z, et al. Guidelines for the management of atopic dermatitis: a literature review and consensus statement of the Philippine dermatological society. J Phil Dermatol Soc. 2020;35-58.
    1. Chen L, Ni Y, Wu X, Chen G. Probiotics for the prevention of atopic dermatitis in infants from different geographic regions: a systematic review and meta-analysis. J Dermatolog Treat. 2022;33(7):2931-2939. doi:10.1080/09546634.2022.2091101
    1. Arkwright PD, David TJ. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol. 2001;107(3):531-534. doi:10.1067/mai.2001.113081

Publication types

LinkOut - more resources